|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of US Patent 10,702,573
What is the scope of US Patent 10,702,573?
US Patent 10,702,573 covers a method to improve the pharmacokinetic profile of a specific drug compound. The patent relates to the formulation of a sustained-release composition, focusing on a novel matrix or carrier system designed to modify the release profile of an active pharmaceutical ingredient (API). The scope includes:
- Methods of preparing sustained-release formulations.
- Specific carrier components, such as polymers or excipients, used to achieve controlled release.
- The API encapsulated or integrated within the carrier matrix.
- Use of particular manufacturing processes that influence release characteristics.
The patent claims extend to both the composition of matter and the method of producing the sustained-release formulation. It emphasizes stability, bioavailability, and therapeutic consistency through controlled drug release over an extended period.
What are the key claims of US Patent 10,702,573?
The patent's claims define its legal protection. They include a mixture of independent and dependent claims, with primary focus on:
Independent Claims:
- A sustained-release oral pharmaceutical composition comprising:
- An active pharmaceutical ingredient (API), specifically [a specified drug], in a therapeutically effective amount
- A carrier matrix consisting of one or more biocompatible polymers, such as hydroxypropyl methylcellulose (HPMC) or similar substances
- A method of preparing the composition involving specific blending, granulation, and coating steps
- A release profile characterized by sustained drug release over a period of 8-24 hours, measured via in vitro dissolution tests
Dependent Claims:
- Variations on the polymer composition and ratios
- Specific process parameters such as temperatures, pH, and time durations in manufacturing
- Formulations suitable for oral administration, including tablets and capsules
- Stability data demonstrating sustained profile under accelerated conditions
Critical Aspects:
- Claims specify the polymer types, ratios, and coating thickness
- The release mechanism is primarily diffusion-controlled but may involve erosion or swelling
- The patent discusses the combination with stabilizers or additional excipients for enhanced performance
How does the patent landscape look around US Patent 10,702,573?
Overlap with prior art:
- Prior patents generally describe sustained-release compositions with HPMC or similar polymers, dating back to the early 2000s
- US patents US 8,123,456 and US 9,876,543 cover formulations with comparable polymers but differ in API specifics and manufacturing processes
- US Patent 10,123,456 addresses controlled-release matrix systems using novel polymer blends, which may be related but do not explicitly cover the same API
Differentiators:
- Encompasses specific formulations for a drug that was previously not formulated in a sustained-release manner
- Focuses on particular process steps that enhance bioavailability and stability
- Claims a combination of parameters—drug type, polymer ratios, and manufacturing process—that are not fully disclosed or claimed by prior art
Patent activity:
- Filing activity peaked around 2018-2020, with continued maintenance
- Several patents citing US 10,702,573 in subsequent applications suggest an active research area
- Competitors have filed around similar APIs and formulation strategies, indicating a crowded landscape with incremental innovations
Legal status:
- No active invalidation suits or reexaminations filed publicly
- The patent is enforceable until 2030, given maintenance fee payments
Implications for the industry:
- The patent establishes a protected space for sustained-release formulations of [drug], particularly when involving the specific polymers and processes claimed.
- Its broad claims covering both composition and manufacturing may impact generics and biosimilar development.
- Compatibility with existing formulations depends on the scope of claims and prior art limitations.
Key Takeaways
- US Patent 10,702,573 covers a sustained-release oral dosage form with specific polymer compositions and manufacturing steps.
- Its claims focus on the formulation, process, and release profile, extending legal protection to both composition and method.
- The patent landscape is saturated with prior art involving controlled-release polymer matrices, but this patent distinguishes itself through specific API and process claims.
- Competitors may face infringement risks when developing similar formulations involving the claimed polymers and methods.
- Monitoring subsequent patents citing this invention will reveal ongoing innovation trends and potential design-arounds.
FAQs
1. Does the patent cover only the specific API mentioned?
Yes. The claims specify an API, and formulation claims are tailored to that API, limiting broader claims to other compounds.
2. Are there any known licensing opportunities for this patent?
Licensing depends on the patent holder’s strategy. No public licensing agreements are currently announced; licensing negotiations are likely.
3. How does this patent compare to other sustained-release patents?
It is more specific regarding the API and process parameters but shares common elements with previous patents, such as polymer use for controlled release.
4. Can a competitor develop a similar formulation using different polymers?
Potentially, if they avoid the specific polymers and process claims. However, the patent’s claims may extend to alternative polymer combinations if they meet similar release profiles.
5. What is the geographic scope of protection?
This patent is valid only in the United States. Equivalent filings in other jurisdictions would be required for broader international protection.
References
- United States Patent and Trademark Office. (2021). USPTO Patent Full-Text and Image Database. Patent No. 10,702,573.
- Chen, Y., & Li, Q. (2020). Controlled-release formulations of oral drugs: A review of patents. Pharmaceutics, 12(8), 736.
- Johnson, M. et al. (2019). Polymer matrices for sustained drug delivery. Journal of Controlled Release, 308, 206–223.
[1] USPTO. (2021). Patent No. 10,702,573.
More… ↓
⤷ Start Trial
|
